肿瘤细胞治疗研究
英文原题：Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
客观缓解率为 84.50%，无病生存期为 2 至 48 个月。
自然杀伤/T细胞淋巴瘤（NK/T-cellL）是一种侵袭性非霍奇金淋巴瘤，对于二线治疗后出现疾病进展或复发的患者，治疗选择有限。提出使用新疗法，如涉及免疫检查点阻断机制的pembrolizumab。本系统综述遵循MOSE指南，检索了PUBMED/MEDLINE、EMBASE和Scopus数据库。共找到14篇文章，报告了pembrolizumab抗PD-1在NK/T-cellL患者中的使用。客观缓解率为84.50%，无病生存期为2至48个月。完全缓解率为61.6%，所报告研究的质量评估显示，病例报告为高和中等置信偏倚水平，临床试验为高偏倚。pembrolizumab及其他抗PD-1是难治/复发性NK/T-cellL的治疗选择，无论PD-L1表达如何，均具有良好的短期和长期结果以及较低的不良事件。
Natural killer/T-cell lymphoma (NK/T-cellL) is an aggressive non-Hodgkin's lymphoma with limited treatment options for patients who experience disease progression or recurrence after second-line treatment. The use of new therapies, such as pembrolizumab, which involves immune checkpoint blockade mechanisms, is proposed. This systematic review followed the MOSE guidelines and searched PUBMED/MEDLINE, EMBASE, and Scopus databases. Fourteen articles were found, reporting on the use of pembrolizumab anti PD-1 in NK/T-cellL patients. The objective response rate was 84.50%, with disease-free survival ranging from two to 48 months. The complete response rate was 61.6%, and the quality of the reported studies was evaluated to be of high and moderate confidence bias levels in case reports and high bias in clinical trials. Pembrolizumab and others anti PD-1 are treatment options for refractory/recurrent NK/T-cellL, regardless of PD-L1 expression, with good short- and long-term results and low adverse events.
MEMBER ACCOUNT
登录成功会直接打开下一页。
